| Dropirenone | Exeltis | ||
| 4 mg ; Tablets |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
Less Than 5
|
||
| None | None | ||
| SLYND is a progestin indicated for use by females of reproductive potential to prevent pregnancy. | |||
|
Yes
| |||
| Slynd | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** | **** ** ***** **, **** | *** ** ** | ********* | ********* | **** ** ***** **, **** | **** ** ***** **, **** | **** ** **** **, **** (***** ******) | **** ** **** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** | *** / *** | *** **, **** | ******* / *** ** ** | ********* ******** | ******* *** **** *** *** **** |
Download ParaIV Report